To reduce damage to healthy peripheral tissues, some modifications are being used such as: (I) combinations of second-generation PS with molecules focused on the target receptor; (II) combinations of PSs with low-density lipoprotein (LDL), since proliferating tumor cells need more cholesterol for cell membrane formation; (III) conjugation of PS with a monoclonal antibody directed to the specific antigen of certain cancer cell; and (IV) the use of surface tumor markers, such as growth factor receptors, transferrin receptors, or hormones (e.g., insulin) (Kwiatkowski et al., 2018). The gene discussed is TFRC; the disease is neoplasm.